Cure My Disease

Don't miss your cure!

 Log in / Sign up

New bone scanners could predict fractures better than current methods

NCT ID NCT06541548

Knowledge-focused Sponsor: Centre Hospitalier Universitaire de Saint Etienne Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study uses two special scanners (HR-pQCT and pQCT) to take detailed pictures of bone and muscle in 1,000 people with conditions that raise the risk of bone loss, like osteoporosis, arthritis, or kidney disease. The goal is to see if these scanners can spot tiny changes in bone structure that current methods miss, which could help doctors better predict and prevent fractures. Participants will have their bones scanned and compared to a healthy control group.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 1,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2026

Expected to finish

May 2035

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: For the patients: Women or men treated at the Saint-Etienne University Hospital and presenting an osteoporotic risk with one of the following associated pathologies: * Osteoporosis defined by: History of a documented brittle bone fracture * Bone fragility: Patient with indication for bone densitometry but no history of fracture * Inflammatory joint disease: * Rheumatoid arthritis * Spondyloarthritis * Chronic kidney disease * Endocrinopathies: * Primary hyperparathyroidism * Constitutional thinness * Anorexia nervosa * Obesity (BMI \>30) * Sarcopenia * Neuropathies - Parkinson's disease For the controls: Acute episode of spinal or radiculalgia (less than one month old) with corticosteroid treatment of less than 1 month Signature of written consent Exclusion Criteria: * No sign written consent For the controls: * Medications inducing bone loss: * anti-aromasin or GnRH agonist for at least 6 months, * corticosteroids (dose ≥ 5 mg/d for 6 months) * anti-epileptic drugs: carbamazepine, phenobarbital, phenytoin, primidone, valproic acid for at least 6 months) * History of fracture due to bone fragility * Taking bone-targeting medication (biphosphonate, teriparatide, strontium ranelate)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anorexia nervosa are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anorexia nervosa Bone Diseases, Metabolic brittle bone disorder chronic kidney disease obesity disorder osteoporosis Parkinson disease primary hyperparathyroidism rheumatoid arthritis spondyloarthropathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bone loss Osteoporosis risk

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Chu Saint Etienne

    RECRUITING

    Saint-Etienne, 42055, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.